Medline ® Abstract for Reference 15
of 'Meningococcal vaccines'
Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep. 2011;60(40):1391.
In April 2011, the Food and Drug Administration approved the use of a quadrivalent meningococcal conjugate vaccine (MenACWY-D) (Menactra, Sanofi Pasteur) as a 2-dose primary series among children aged 9 through 23 months. Vaccination with meningococcal polysaccharide vaccine (MPSV4) is not recommended for children aged<2 years because of low immunogenicity and short duration of protection in this age group.